US/UK/Canada

Share

Contacts

  • Linda Wakeham

    Head of Marketing & Communication


    Kungsgatan 8, Stockholm
    +46 730 28 30 30
    http://mavatar.com

    • Links

    Quotes

    Initial exploration of Mavatar Discovery has identified biological signals that could be highly relevant to our current Alzheimer’s research identifying new targets.
    Tomas Deierborg, Professor of Experimental Medical Science at Lund University
    This collaboration demonstrates the value of combining clinical expertise with structured, data-driven resources. It’s encouraging to see how these tools are already informing research and opening new possibilities for more precise and effective IBD care.
    Dr. Ann-Sofie Backman, Associate Professor at Karolinska Institutet and Attending Physician in the Gastroenterology Unit at Ersta Hospital.
    Alongside our broader efforts to engage the life science community around data-driven precision medicine, we also want to lower barriers to advanced analytics in areas of high unmet need.
    Danuta Gawel, Chief Research & Development Officer at Mavatar
    We are pleased to collaborate with Sobi, whose deep commitment to rare diseases aligns strongly with our mission. Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.
    Johan Juhlin, CEO and Co-founder of Mavatar.
    Scientists no longer need to spend months cleaning datasets or building complex pipelines. With Mavatar Discovery, they can explore disease mechanisms, identify biomarkers, and generate pilot data in minutes - all without writing a single line of code.
    Johan Juhlin, CEO and Co-Founder of Mavatar
    We are very pleased to welcome Ulrika to Mavatar. Her extensive experience and broad network within Life Science make her a key part of our efforts to build strong partnerships and to further establish Mavatar in both the Nordic and global markets
    Johan Juhlin, CEO & Co-founder Mavatar
    Mavatar’s technology is a game-changer for drug development and personalized healthcare.
    Linda Wakeham
    "This investment brings us closer to revolutionizing global healthcare with personalized medicine."
    Johan Juhlin, CEO at Mavatar
    Pick a time period -
    Tags ( Active)

    Mavatar Launches Alzheimer’s Disease Networks at AD/PD 2026

    Mavatar today announced the addition of networks of Alzheimer’s disease, glioma and other neurological disorders to its research platform, Mavatar Discovery, enabling researchers and pharmaceutical scientists to explore neurodegenerative disease biology at a systems level. The new resource will be formally introduced to the scientific at the AD/PD International Conference on Alzheimer's and Parkinson's Diseases taking place in Copenhagen from March 17–21, 2026.Mavatar Discovery is a data-driven research platform designed to help scientists move from gene lists to biological mechanisms. By

    Mavatar Delivers New Data-Driven Resources to Advance Precision Medicine for IBD

    Mavatar, a global specialist in AI and data-driven precision medicine solutions, announces a key milestone in its contribution to the national project “Precision Medicine in Inflammatory Bowel Disease (IBD)”, funded by Vinnova. The company has developed an integrated transcriptomic resource designed to support a broad range of studies within precision medicine for patients with IBD.The initiative, led by RISE and involving a broad consortium of academic, clinical, and industry partners, aims to improve diagnosis, treatment, and long-term outcomes for the more than 85,000 people living with

    Mavatar Launches Rare Disease Discovery Award

    - New initiative to support research where data is scarce Mavatar, a global specialist in AI- and data-driven precision medicine solutions, today announced the launch of the Mavatar Rare Disease Discovery Award 2026. This global initiative serves to support data-driven exploration of disease biology and drug development.The awards will be granted quarterly throughout 2026, enabling scientists across disciplines and geographies to apply advanced analytical methods to some of the most challenging and underserved areas in biomedical research. “Rare disease research is driven by clinical

    Mavatar Enters Research Collaboration with Sobi

    Mavatar, a global specialist in AI- and data-driven precision medicine solutions, today announces the start of a non-clinical research collaboration with Sobi, a global biopharmaceutical company focused on rare diseases.The collaboration will explore interferon gamma (IFNγ)-associated biological pathways using Mavatar’s large-scale analysis platform, Mavatar Discovery, which integrates and contextualizes publicly available transcriptomic datasets. The research aims to generate structured, data-driven insights that can support scientific understanding in selected disease areas. “We are

    From Sweden to the world: Mavatar launches a platform that drastically shortens the time to biological insights

    Stockholm, Sweden – 20 Nov 2025 - Mavatar, the Swedish biotech company pioneering AI- and data-driven precision medicine, today announced the full global commercial launch of Mavatar Discovery, its next-generation platform that enables researchers to analyze complex biological data and uncover disease insights in hours instead of months.Following a successful early release, Mavatar Discovery is now available worldwide - marking a major step toward making high-resolution, data-driven discovery accessible to research teams everywhere. “The global launch of Mavatar Discovery signals a new

    Mavatar recruits Nordic Life Science profile Ulrika Nyberg

    Takes key role in global expansion phase Mavatar, a pioneer in AI- and data-driven precision medicine, is accelerating its momentum following last week’s early commercial launch of the research platform Mavatar Discovery. The company has appointed Ulrika Nyberg as Head of Strategic Partnerships, with a mandate to drive strategic collaborations as Mavatar enters its next growth phase. This recruitment marks the beginning of a broader expansion in the Nordics and a strengthened international presence.Ulrika Nyberg is a well-known figure in the Nordic Life Science community. She brings over

    Mavatar Strengthens Leadership Team with Linda Wakeham as Head of Marketing & Communication

    Mavatar, a Swedish pioneer in AI-driven precision medicine, announces the recruitment of Linda Wakeham. Wakeham joins Mavatar from Kronans Apotek, where she served as Head of Communications and PR for the past six years. At Mavatar, she will join the leadership team as Head of Marketing & Communication and will lead the company’s marketing strategy to drive growth and strengthen Mavatar’s position as an innovative force in precision medicine.“We are excited to welcome Linda Wakeham to Mavatar. Her extensive experience in communication and marketing, combined with her entrepreneurial spirit

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media